1160 related articles for article (PubMed ID: 10459170)
41. The non-peptidic delta opioid receptor agonist TAN-67 enhances dopamine efflux in the nucleus accumbens of freely moving rats via a mechanism that involves both glutamate and free radicals.
Fusa K; Takahashi I; Watanabe S; Aono Y; Ikeda H; Saigusa T; Nagase H; Suzuki T; Koshikawa N; Cools AR
Neuroscience; 2005; 130(3):745-55. PubMed ID: 15590157
[TBL] [Abstract][Full Text] [Related]
42. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
Hewton R; Salem A; Irvine RJ
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1051-7. PubMed ID: 17714093
[TBL] [Abstract][Full Text] [Related]
43. Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study.
Sarre S; Herregodts P; Deleu D; Devrieze A; De Klippel N; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):277-85. PubMed ID: 1407014
[TBL] [Abstract][Full Text] [Related]
44. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
45. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
46. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.
Kääriäinen TM; Lehtonen M; Forsberg MM; Savolainen J; Käenmäki M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):50-8. PubMed ID: 17971064
[TBL] [Abstract][Full Text] [Related]
48. The effect of antiparkinsonian drugs on oxidative stress induced pathological [3H]dopamine efflux after in vitro rotenone exposure in rat striatal slices.
Milusheva E; Baranyi M; Kormos E; Hracskó Z; Sylvester Vizi E; Sperlágh B
Neuropharmacology; 2010; 58(4-5):816-25. PubMed ID: 19995567
[TBL] [Abstract][Full Text] [Related]
49. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
Alam M; Schmidt WJ
Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
[TBL] [Abstract][Full Text] [Related]
50. Single administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline increases the extracellular concentration of dopamine in rat striatum.
Katagiri N; Abe K; Kitabatake M; Utsunomiya I; Horiguchi Y; Hoshi K; Taguchi K
Neuroscience; 2009 Jun; 160(4):820-8. PubMed ID: 19285542
[TBL] [Abstract][Full Text] [Related]
51. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation.
Kannari K; Tanaka H; Maeda T; Tomiyama M; Suda T; Matsunaga M
J Neurochem; 2000 Jan; 74(1):263-9. PubMed ID: 10617128
[TBL] [Abstract][Full Text] [Related]
52. Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine.
Marti M; Manzalini M; Fantin M; Bianchi C; Della Corte L; Morari M
J Neurochem; 2005 Apr; 93(1):195-205. PubMed ID: 15773919
[TBL] [Abstract][Full Text] [Related]
53. Detection of levodopa, dopamine and its metabolites in rat striatum dialysates following peripheral administration of L-DOPA prodrugs by mean of HPLC-EC.
Cannazza G; Di Stefano A; Mosciatti B; Braghiroli D; Baraldi M; Pinnen F; Sozio P; Benatti C; Parenti C
J Pharm Biomed Anal; 2005 Jan; 36(5):1079-84. PubMed ID: 15620535
[TBL] [Abstract][Full Text] [Related]
54. Tetrahydrobiopterin stimulates L-DOPA release from striatal tissue.
Abreu-González P; González-Hernández T; Afonso-Oramas D; Cruz-Muros I; Barroso-Chinea P; González MC
Eur J Pharmacol; 2006 Jul; 541(1-2):33-7. PubMed ID: 16750826
[TBL] [Abstract][Full Text] [Related]
55. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
56. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.
Smith AD; Kozlowski DA; Bohn MC; Zigmond MJ
Exp Neurol; 2005 Jun; 193(2):420-6. PubMed ID: 15869944
[TBL] [Abstract][Full Text] [Related]
57. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.
Yamamura S; Ohoyama K; Nagase H; Okada M
Neuropharmacology; 2009 Sep; 57(3):322-31. PubMed ID: 19482038
[TBL] [Abstract][Full Text] [Related]
58. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
[TBL] [Abstract][Full Text] [Related]
59. Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata.
Yamamoto N; Pierce RC; Soghomonian JJ
Brain Res; 2006 Dec; 1123(1):196-200. PubMed ID: 17027936
[TBL] [Abstract][Full Text] [Related]
60. Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain.
Fisher A; Starr MS
Brain Res; 2000 Jun; 868(2):268-74. PubMed ID: 10854579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
